bioCSL supports public health efforts in Laos with donation of more than 700,000 doses of seasonal influenza vaccine

   bioCSL supports public health efforts in Laos with donation of more than
                 700,000 doses of seasonal influenza vaccine

Participation in innovative public-private collaboration helps improve
vaccination infrastructure, expand patient reach in partner countries

PR Newswire

KING OF PRUSSIA, Pa., April 28, 2014

KING OF PRUSSIA, Pa., April 28, 2014 /PRNewswire/ --bioCSL, formerly CSL
Biotherapies, has announced the donation of more than 700,000 doses of its
influenza vaccine to the Partnership for Influenza Vaccine Introduction, an
innovative program - spearheaded by the U.S. Centers for Disease Control and
Prevention (CDC) and the Task Force for Global Health (TFGH) - that helps low-
and middle-income countries reduce annual morbidity and mortality from
influenza. The program helps eligible countries create or expand public
vaccination program infrastructures within their borders. This year marks the
second consecutive year that bioCSL has donated vaccine to the program.

"Influenza is a common viral infection that can sometimes result in serious
complications," said Marie Mazur, President, bioCSL Inc. "For this reason, it
is critical that influenza vaccine is made available to everyone - especially
in areas of the world where robust healthcare systems are not in place to
facilitate the acquisition and distribution of vaccine. The Partnership is
actively addressing this need on a large scale, and we at bioCSL are pleased
to be partnering in this effort for the second year in a row by making a
significant donation of our vaccine."

Influenza, commonly called "the flu," causes upwards of 49,000 deaths annually
in the U.S., and tens of thousands more around the world, mostly among high
risk populations, which can include the elderly, those with pre-existing
diseases such as asthma and diabetes, and pregnant women. It is also a
frequent cause of hospitalizations due to pneumonia and other life-threatening
complications.

According to the CDC, research has shown that getting vaccinated is the best
way for each individual to reduce the threat of contracting influenza. The
Partnership for Influenza Vaccine Introduction began as a pilot program in
Laos in 2011, winning the CDC Director's Award for Innovation, and has
expanded each year since, adding new partners, new countries and additional
patient populations. With the effort's significant impact, several other
countries have made requests to participate.

"This year's vaccination campaign in Laos would not be possible without the
flu vaccine donations provided by private organizations," said Dr. Joseph
Bresee, Chief of the Epidemiology and Prevention Branch in CDC's Influenza
Division. "Private donors' contributions allow eligible countries to establish
and expand their own annual influenza vaccination programs with guidance from
CDC, Task Force for Global Health, World Health Organization and other public
health partners. In short, vaccine donations are absolutely critical to the
mission."

According to the CDC, influenza outbreaks tend to follow regular seasonal
patterns, which vary in different geographies. Flu season in Laos begins
approximately in June, making the bioCSL donation especially timely, and the
company notes that supplies will begin shipping soon.

About bioCSL Inc.
bioCSL Inc., located in King of Prussia, Pennsylvania, is the United States
headquarters of bioCSL. Parent company, CSL Limited, has manufactured
influenza vaccine in its Melbourne, Australia, facility since 1968. CSL
Limited has made a $60 million (U.S.D.) investment in plant and equipment to
double capacity at its Melbourne facility, making it one of the largest
vaccine manufacturing facilities in the world. CSL-branded influenza vaccines
are approved in 28 countries. At bioCSL Inc., delivering vaccines is our
mission, protecting lives our passion. The CSL Group, which also includes CSL
Research & Development, CSL Plasma, and CSL Behring, has more than 11,000
employees globally and operates in 26 countries around the world.

Media contact:

Sheila Burke

bioCSL

610-290-7403

SOURCE bioCSL Inc.
 
Press spacebar to pause and continue. Press esc to stop.